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Self-amplifying replicon RNA (RepRNA) promotes expansion of mRNA templates
encoding genes of interest through their replicative nature, thus providing increased
antigen payloads. RepRNA derived from the non-cytopathogenic classical swine fever
virus (CSFV) targets monocytes and dendritic cells (DCs), potentially promoting prolonged
antigen expression in the DCs, contrasting with cytopathogenic RepRNA. We engineered
pestivirus RepRNA constructs encoding influenza virus H5N1 (A/chicken/Yamaguchi/7/
2004) nucleoprotein (Rep-NP) or hemagglutinin (Rep-HA). The inherent RNase-sensitivity
of RepRNA had to be circumvented to ensure efficient delivery to DCs for intracellular
release and RepRNA translation; we have reported how only particular synthetic delivery
vehicle formulations are appropriate. The question remained concerning RepRNA
packaged in virus replicon particles (VRPs); we have now compared an efficient
polyethylenimine (PEI)-based formulation (polyplex) with VRP-delivery as well as naked
RepRNA co-administered with the potent bis-(3’,5’)-cyclic dimeric adenosine
monophosphate (c-di-AMP) adjuvant. All formulations contained a Rep-HA/Rep-NP
mix, to assess the breadth of both humoral and cell-mediated defences against the
influenza virus antigens. Assessment employed pigs for their close immunological
relationship to humans, and as natural hosts for influenza virus. Animals receiving the
VRPs, as well as PEI-delivered RepRNA, displayed strong humoral and cellular responses
against both HA and NP, but with VRPs proving to be more efficacious. In contrast, naked
RepRNA plus c-di-AMP could induce only low-level immune responses, in one out of five
pigs. In conclusion, RepRNA encoding different influenza virus antigens are efficacious for
inducing both humoral and cellular immune defences in pigs. Comparisons showed that
packaging within VRP remains the most efficacious for delivery leading to induction of
immune defences; however, this technology necessitates employment of expensive
complementing cell cultures, and VRPs do not target human cells. Therefore, choosingorg January 2021 | Volume 11 | Article 6223851
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particularly in the context of the current coronavirus pandemic.Keywords: self-amplifying replicon RNA, virus replicon particle, polyplexes, influenza vaccines, humoral and
cellular immune response, c-di-AMP adjuvantINTRODUCTION
Current influenza vaccines display several disadvantages, such as
limited antigen batches, reliance on cell culture or egg
production, risk from potential reversion to virulence and
interference from pre-existing immunity. Reversion can be
circumvented by employing inactivated, split or subunit
vaccines, as seen with the majority of current vaccines.
However, due to the limited amount of virus antigen present
and the absence of self-replication to increase the immunogenic
load, the efficacy of these current vaccines is limited. Indeed, they
tend to favor induction of humoral defences with poor cell-
mediated representation. This relatively poor immunogenicity is
also reflected in the need for reformulation for revaccination on
an annual basis, due to influenza virus seasonal antigenic drift. In
this context, vaccine efficacy can be enhanced by ensuring the
promotion of both humoral and cell-mediated defences, as
observed with convalescent immunity following virus infection.
Replicating vaccines – such as live-attenuated and vector-based
vaccines – providing several rounds of antigen production would
fulfil such a role (1–4). Yet, live and vector-based vaccines are not
without risk.
mRNA-based vaccines are safe and produced under cell-free
conditions. In the context of pandemics, they offer potential for
rapid vaccine design. Effectively, three candidates are currently in
clinical trials to prevent COVID-19: mRNA-1273 (Moderna),
BNT-162 (BioNTech), CVnCoV (CureVac). However, a recent
study showed that for equivalent levels of protection, self-
amplifying (self-replicating) replicon RNA (RepRNA) required
a 64-fold lower dose and resulted in prolonged and increased
transgene expression (5). RepRNA are more complex and larger
molecules than mRNA, encoding a replication machinery and
thus resulting in expanded translation of encoded antigens; being
derived from defective virus genomes, progeny virus production
is excluded (6–14). The replicative nature of RepRNA provides
several rounds of antigen production, thus enhancing the antigen
dosage available for activating humoral and cell-mediated
immunity (CMI), as well as the duration and therefore
robustness of that response. These latter points are important
in the context of the relative cytopathogenicity of the RepRNA,
related to the virus for which it was derived.
It is also important to consider the critical role of dendritic cells
(DCs) in immune responses (11, 15, 16). They collect antigen in the
periphery, transport it into lymphoid tissues andorgans, process the
antigen, and promote activation of bothhumoral and cell-mediated
immunity (17–19). In addition tovaccine interactionwithDCs, one
should also consider the impact of adjuvants selected for vaccine
formulation, in terms of the DC maturation essential for efficient
immune response induction.org 2Vaccine interaction with DCs should promote DC
functionality in a durable manner, the latter benefiting from a
vaccine based on a non-cytopathogenic rather than
cytopathogenic virus. Most RepRNA are derived from human
pathogens, such as the widely employed alphaviruses. The
cytopathogenic nature of alphaviruses can impact on the
duration of RepRNA-dependent induction of immune
responses. An additional constraint arises from the 5’-cap of
alphavirus RNA; recognition of this 5’-cap by cellular innate
defences will promote cellular attack against the RepRNA. In
contrast, RepRNA derived from classical swine fever virus
(CSFV) do not possess these encumbrances. Firstly, they are
derived from a non-cytopathogenic porcine pestivirus non-
pathogenic for humans. Secondly, they do not carry a 5’-cap,
and any viral RNA structure-mediated innate immune activation
of the target cells is impeded by the RepRNA-encoded leader
autoprotease Npro by a yet unknown mechanism leading to
efficient proteasomal degradation of interferon regulatory
factor 3 (20).
In order to assess the potential of RepRNA derived from non-
cytopathogenic CSFV, we engineered RepRNA to encode
influenza virus antigens, including NP or HA from the H5N1
isolate A/chicken/Yamaguchi/7/2004 (H5N1). However, the
specific nature of RepRNA requires protection to survive in
vivo and assistance to cross the cell membrane barrier,
particularly to target DCs for internalization (11). Unprotected
(“naked”) RepRNA suffer from RNA instability due to
particularly high sensitivity to RNase damage of their
functionality, and a poor capacity for internalisation into cells.
This led to development of virus-like replicon particles (VRPs)
(14, 21, 22), or synthetic, nanoparticulate delivery vehicles
formulated as chitosan-based particles, polyplexes, or lipoplexes
(23–27). Although many of these synthetic formulations were
unsuccessful at delivering RepRNA to DCs for translation,
particular formulations promote in vitro RepRNA delivery
and translation, however, still inferior to what is obtained
with VRPs.
Of course, RepRNA translation in vitro is only of value if also
observed in vivo. Electroporation of nucleic acids has been
reported in vivo, but remains painful and does not guarantee
DC targeting (28). This leaves the question of how VRP-based
delivery would compare with synthetic, nanoparticulate vehicles
as an alternative and feasible strategy for delivering RepRNA to
DCs. It is also important that the efficacy is assessed in different
animal species, especially one with immune responsiveness more
closely related to humans. In addition, one can take advantage of
potent synthetic adjuvants to enhance further the immune
response induction. Accordingly, we assessed RepRNA vaccine
delivery by VRP in comparison with a PEI-based polyplexJanuary 2021 | Volume 11 | Article 622385
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observations were related back to the in vitro characteristics of
each delivery system. For in vivo assessment, the delivery vehicles
carrying the RepRNA were co-administered with the potent
adjuvant bis-(3’,5’)-cyclic dimeric adenosine monophosphate
(c-di-AMP), monitoring the development of both humoral and
cell-mediated immune responses as required for efficacious
vaccination against influenza (29–33). This study used a
murine model conventionally employed with influenza vaccine
pre-clinical evaluation, and a porcine model, due to its closer
immunological relationship to humans, in particular in terms of
DCs, and being a natural host for influenza virus (34).MATERIALS AND METHODS
Reagents and Cell Lines
Porcine SK-6 cells (35) were kindly provided by Professor
Maurice Pensaert (University of Gent, Belgium). The synthesis
and purification of the mucosal adjuvant c-di-AMP was
described in Ebensen et al. (30).
Self-Amplifying Replicon RepRNA
Rep-HA and Rep-NP constructs were already described
elsewhere (24–26) and are schematized in Figure 1A. They
were derived from plasmid pA187-1 that carries a full-length
cDNA copy of the genome of the CSFV strain Alfort/187 (CSFV
parent) (36) from which the Erns coding sequence was deleted
(DErns) to engineer the original DErns RepRNA (RepRNA). The
Rep-NP was obtained by insertion of the NP gene from influenza
virus A/chicken/Yamaguchi/7/2004 (H5N1) (37) via a NotI
restriction endonuclease site at the 3′ end of the Npro coding
sequence, upstream of an internal ribosomal entry site (IRES)
from encephalomyocarditis virus (EMCV) that permits re-
initiation of the translation of the downstream polyprotein. For
Rep-HA, a copy of the CSFV C coding sequence was placed
between the Npro and the HA glycoprotein coding sequence of
the same influenza virus with HA lacking the 5’-terminal 16
codons of the signal peptide. For this, a Npro-C-HADNA cassette
was generated by PCR and inserted between the ClaI site of Npro
and theNotI site. This ensures the correct ER translocation of the
HA glycoprotein by the Erns signal peptide encoded at the 3-
terminal region of C.
Generation of VRPs
VRPDErns carrying a genome with a complete deletion of the Erns
coding sequence were produced typically by transfection of 8 x
106 SK-6(Erns) cells with 1 mg A187-DErns replicon RNA. The SK-
6(Erns) cells express the Erns protein required for the generation
of VRPDErns by trans-complementation (38, 39). The infectious
titre of the VRP was determined in SK-6(Erns) cells by end-point
dilution and expressed in 50% tissue culture infective doses
(TCID50)/ml according to standard protocols. Based on RT-
qPCR quantification of infectious CSFV (of known titre) and of
the corresponding full-length genomic in vitro transcripts (1µg
CSFV genome RNA transcripts = 1.5 x 1011 molecules), 1Frontiers in Immunology | www.frontiersin.org 3TCID50 of CSFV corresponds approximately to 10
3 genome
equivalents (Hinojosa and Ruggli, unpublished).
Generation of Synthetic Delivery Vehicles
Carrying RepRNA
The generation of chitosan-based nanoparticle delivery
formulations, and the PEI-based polyplex nanoparticles were
as described previously (23–27).
Briefly, for polyplexes, RepRNA incorporated into polyplex
formulations were as follow: [Rep-NP/PEI-4,000 (1:3)] and
[Rep-HA/PEI-40,000 (1:2)/(Arg)9]. For Rep-NP, RepRNA :
PEI-4,000 (weight:weight) ratio of (1:3) was mixed by
vortexing (4 s, 10 mM HEPES buffer, pH7.4). After 30 min of
incubation at room temperature (RT), volumes were adjusted
with serum-free Opti-MEM®. For Rep-HA, PEI-40,000 solution
was first mixed to 0.5 µM of (Arg)9 and further incubated for
30 min at RT. Then, RepRNA was added to the [PEI/(Arg)9] core
with a RepRNA : PEI (weight:weight) ratio of (1:3), incubate for
30 min at RT. Volumes were adjusted with serum-free
Opti-MEM®.
RepRNA Functional Assay Adapted
to Confocal Microscopy
All batchesofRepRNAproductionused for the trialwere testedbya
functional assay adapted to confocal microscopy; the number of
cells (expressingCSFVE2) and the geneof interest (GOI)HAorNP
were monitored. This assay was described elsewhere (24, 25) and
employed reference SK-6 cells that were mixed with RepRNA and
electroporated immediately. These cells are very efficient at
propagating CSFV and provide a reliable reference to support
RepRNA replication (23, 24, 26, 35, 39, 40). SK-6 cell growth is
facilitated by Eagle’s Minimal Essential Medium (MEM Earle’s,
consisting of MEM supplemented with Earle’s salts, 2 mM L-
glutamine, and 7% (v/v) pestivirus- and Mycoplasma-free horse
serum). The readouts were measured after 48 h; illustrations of
E2+NP+ foci following electroporation of SK-6 cells are shown in
Figure 1B. The criterion for inclusion of a given RepRNA batch in
the trial is detection of E2+GOI+ foci in the fourth well of a tenfold
serial dilution (10-4mg ofRepRNAper 8 x 102 SK-6 transfected cells
seeded on a pre-formed monolayer of 3 x 105 cells). Ultimately, all
the positively-selected RepRNA batches were thawed the day of
administration in pigs.
Primary porcine blood DCs (bDCs) were isolated/derived as
described (41). Then, they were grown in 8-well fibronectin-
coated Lab-Tek® chambers (Nunc, Wiesbaden, Germany).
Before exposure to VRP or [RepRNA/PEI], bDCs were washed
to remove serum. After 1-3h, cells were washed again and
cultured (39°C; DMEM/10%-porcine-serum/50 U/ml-GM-
CSF/100 U/ml-IL-4) for 96 h. Labeling used anti-E2 (HC/TC
26, kindly provided by Irene Greiser-Wilke, Hannover,
Germany) and anti-NP (HB6J; ATCC, Rockville MD, USA)
antibodies. DC-surface staining used WGA-Alexa633
(Molecular Probes/Invitrogen), 10 min on ice, then washed,
fixed (4% PFA, 10 min), permeabilized (Perm/Wash-Buffer-I,
BD Biosciences, Allschwil, Switzerland). Slides were mounted in
Mowiol for confocal microscopy.January 2021 | Volume 11 | Article 622385
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The immunization of mice and rabbits using the chitosan-based
nanoparticle (NGA) delivery formulations has been described
previously (23). Briefly, RepRNA was incorporated into NGA,
and 100 µl were used per dose for vaccination of Balb/c mice and
New Zealand white rabbits. Each dose comprised 0.2 µg of Rep-
HA in 50 µl plus 0.2 µg of Rep-NP in 50 µl; mice received one
dose for each RepRNA mixed together, while rabbits receivedFrontiers in Immunology | www.frontiersin.org 4twice this dose. The NGA vaccines were adjuvanted with 0.5 µg
c-di-AMP adjuvant. Animals were vaccinated subcutaneously at
days 0, 14, and 28, and bled from the tail vein (mice) or ear
(rabbits). Anti-HA and anti-NP titers were assessed by indirect
enzyme-linked immunosorbent assay using recombinant HA
(H5 Vietnam 2004) and NP as antigen.
The immunization of mice using the polyplex delivery
formulations has also been described previously (24, 25).A
B
C
FIGURE 1 | Prime-boost protocol for i.d. pig immunization. (A) Schematic representation of the CSFV genome (parent virus genome) employed for generating the
RepRNA constructs: the deletion of the Erns coding sequence (DErns) and the inserted GOI (Rep-NP, Rep-HA) are shown. (B) Illustration of RepRNA functional assay
by confocal microscopy, adapted from the infection center assay (ICA) reported elsewhere (25). In this example, SK-6 cells were electroporated with Rep-NP, after
what we performed a tenfold serial dilution of the transfected cells (corresponding to 10-1 µg RepRNA and 8 x 105 cells per 100 µl in the first dilution to 10-4 µg
RepRNA and 800 cells per 100 µl in the 4th dilution). 100 µl of each dilution containing electroporated cells were transferred to the corresponding Lab-Tek® wells
and let to adhere to 3 x 105 pre-seeded SK-6 cells for 4–6 h in the 37°C incubator in MEM/glutamax/7%v/v-horse-serum. Then, the medium was replaced, and cells
were cultured for 48 h at 37°C. The staining protocol involved fixation, permeabilisation and labelling with antibody against NP (green) and E2 (red); cell surfaces were
stained with WGA-Alexa633 (gray). (C) Illustration of the prime-boost protocol for i.d. pig immunization. On day 56 the peripheral blood and the draining superficial
cervical dorsal LNs were collected from sacrificed pigs.January 2021 | Volume 11 | Article 622385
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purchased from Harlan (Germany). OVA-TCR transgenic
mice C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I) were bred at
the animal facility of the HZI. All mice were kept under SPF
conditions in compliance with the guidelines of the Institutional
Animal Use and Care Committee. OT-I (CD8) T cells were
sorted from cervical LNs of naive mice (Thy1.1+) using Miltenyi
CD8 T cell isolation kits. Then, 2.5 × 105 OT-1 CD8 T cells were
injected intravenously into recipient C57BL/6 mice, 6–8 week old
(Thy1.1−) (Day-1). At day 0, mice were vaccinated
intrapulmonary with 7.5 mg Rep-OVA and 7.5 mg adjuvant c-
di-AMP. Cervical LNs were collected at day 7.
Immunization of Pigs (Prime-Boost
Protocol)
All pigs were obtained from the specific-pathogen-free (SPF)
breeding facility of the IVI. Male and female 10-week-old Large
White SPF pigs were assigned randomly to three groups of five
animals (n=5) housed in separate stables. The experiment
was blinded.
Each pig was immunized by intradermal (i.d.) injection of
Rep-HA and Rep-NP, co-administered or not with 250 mg of c-
di-AMP as adjuvant. During the past few years, we have
accumulated data confirming that naked RepRNA is unable
to penetrate into DCs for translation, nor does it show evidence
for translation in vivo. Accordingly, a control group of naked
RepRNA alone would have provided no new insights. Instead,
groups were constituted as follow: naked RepRNA in
association with c-di-AMP (group “RepRNA + c-di-AMP”),
reference points for the assay; RepRNA formulated into PEI
polyplex delivery vehicles in association with c-di-AMP (group
“[RepRNA/PEI] + c-di-AMP”); or RepRNA packaged into
VRPs (group “VRP, no adjuvant”). Within each vaccine of
the groups “RepRNA + c-di-AMP” and “[RepRNA/PEI] + c-
di-AMP”, 50 µg of Rep-HA and 50 µg Rep-NP were applied in
a total volume of 0.5 to 0.8 ml each, distributed in five to eight
different spots of 0.1 ml each in the dermis of the right and left
neck, respectively. For the “VRP” group, 5x106 TCID50 of
VRP-[Rep-HA] and 5x106 TCID50 of VRP-[Rep-NP] were
applied in a total volume of 0.5 to 0.8 ml each, distributed in
five to eight different spots of 0.1 ml each in the dermis of the
right and left neck, respectively. 5x106 TCID50 of VRP
corresponds approximately to 5x109 viral genomes (see
above), which represents a weight of 33 ng of RNA (1µg
CSFV genome = 1.5x1011 genome molecules, see above).
Thus, compared with VRP, approximately 103 times more
RepRNA (50 µg) was applied with the PEI polyplex
delivery system.
A total of three immunizations were applied with 3 weeks
interval. At day 56, animals were euthanized by electrical
stunning and subsequent exsanguination, blood was taken and
superficial cervical dorsal lymph nodes (LNs) were collected
(Figure 1C). Importantly, naked RepRNA co-administered
with c-di-AMP, the VRPs and the PEI-complexes were well
tolerated by the animals, and no side effects were observed over
the 56-day observation period (data not shown).Frontiers in Immunology | www.frontiersin.org 5HA and NP Restimulation of Freshly
Isolated Cells
PBMC were isolated by centrifugation on a Ficoll-paque density
gradient (1.077 g/L, GE Healthcare. Chicago, IL, USA).
Harvested LNs were washed with sterile PBS+/+, cut in small
pieces, and incubated in 15 ml of pre-warmed PBS+/+ containing
0.36 mg/ml collagenase D (Sigma-Aldrich) and 100 µg/ml DNase
I (Sigma-Aldrich) during 30 min under agitation at 37°C. The
enzymatic reaction was stopped by adding 50 ml of PBS-/- with 5
mM EDTA solution. The cells were then filtered through a 100
µm and 70 µm filter (BD Biosciences, Allschwil, Switzerland),
washed three times with PBS-/- (4°C). Cell count and viability
was done with Türk’s solution under the microscope.
Isolated PBMCs or LN cells for T cell and B cell restimulation
assays (1 x 106 cells/ml) were cultured in DMEM/10%FBS with 1
µg/ml recombinant HA/NP (Immune Technology Corp., New
York, U.S.A.), 1 µg/ml recombinant E2 [produced in cultures of
insect cells infected with the baculovirus vector (42)], or without
(unstimulated). As a positive control, the cells from all samples
were cultured with 10 µg/ml of Concanavalin A (Con A) (Sigma).
Importantly, those experiments were performed in the absence
of antibiotics. After 3 or 5 days at 39°C, cells were harvested and
analyzed by flow cytometry (FCM).
Flow Cytometry
FCM combination staining for T cell and B cell proliferation by
CellTrace™ Violet (Life Technology) dilution employed: CD3
(BB23-8E6-8C8) (BD Biosciences), CD4 (PT90A), CD8 (76-2-
11), CD21 (BB6.11C9.6), and IgM (PIG 45A) (all from VMRD,
Germany). 5x105 eventswere stained for each sample and thewhole
tube was acquired. Analysis gate was placed on FSChigh cells, as
proliferating T cells are located at this area (24). Proliferating
CellTracelow cells were scored as a percentage of the FSChigh cell
gate. Data were acquired using FACSCanto II (Becton-Dickenson),
and analyzed with Flowjo software (version 9, Treestar, USA).
Serum Antibodies
Anti-HA and anti-NP antibody titers were assessed by indirect
ELISA as described previously (23).
Statistical Analysis
Statistical analysis was done using the GraphPad Prism 8
software (GraphPad software, La Jolla, CA, USA). The p-values
were calculated using one-way ANOVA and Bonferroni
nonparametric post-test. Data are presented as box and
whisker plots (* p <0.05, ** p <0.01, *** p <0.001).RESULTS
Delivery of RepRNA in Rabbits and Mice
Comparison of the previously reported chitosan-alginate
nanoparticulate (NGA) delivery with VRPs using RepRNA
encoding influenza virus HA and NP showed a clear advantage
for VRP delivery in rabbits (Figure 2A). In contrast, the NGA
delivery appeared to be the more advantageous in mice, in termsJanuary 2021 | Volume 11 | Article 622385
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three immunizations before a detectable specific antibody
response was obtained (Figure 2B). Moreover, VRP efficiency
in mice was variable between experiments, with little or no
specific antibody induced in certain cases (data not shown).
The readouts obtained with the NGA in mice also showed
variation between experiments, as did the use of lipids (27) or
polyplexes (24, 26) for delivery. It was discovered that the
efficiency of polyplex delivery leading to translation of the
RepRNA was highly dependent on the PEI formulation (24),
and it appears that the potential for lipoplexes suffers from the
same encumbrance (27). Finally, we considered the efficiency ofFrontiers in Immunology | www.frontiersin.org 6polyplex delivery formulations to induce cellular immune
response. Antigen-specific proliferation of OT-I CD8+ T cells
were assessed 7-days post-immunisation in cells collected from
cervical LNs. Reduced CFSE signal from preloaded cells (due to
cell division distributing the dye to daughter cells) was employed
as readout. In case of the CD8+ T-cell compartment,
immunisation with polyplex was efficient to induce
CD8+ proliferative responses compared to PBS and naked
RepRNA treated mice. These in vivo results demonstrate that
polyplexes combined with the mucosal adjuvant c-di-AMP
promotes translation of encoded antigens by DCs to stimulate
proliferation of GOI-specific CD8+ T cells (Figure 2C), makingA
B D
C
FIGURE 2 | Virus replicon particle (VRP) and NGA deliver RepRNA for translation in vivo. (A, B) Mice and rabbits were injected subcutaneously at 0, 14, and 28
days. Rep-HA and Rep-NP were delivered in NGA or VRP; all vaccines were adjuvanted with c-di-AMP adjuvant. Serum samples were assessed for anti-HA and
anti-NP antibodies by ELISA and titers estimated at the times shown. (C) Adoptive transfer studies in mice have been performed in order to investigate the potential
of the polyethylenimine (PEI) formulations to stimulate cellular immune responses. In brief, 24 h prior vaccination of wild type mice, CFSE labeled Thy1.1 CD8+ T cells
of antigen-specific TCR transgenic mice were injected intravenously. 7 days later, cervical LNs of transplanted mice were collected and the proliferative capacity of
the CFSE labeled Thy1.1 CD8+ T cells was analyzed by flow cytometry. Cell number as well as the number of cell divisions correlate with both strength of the
stimulated cellular response and vaccine delivery efficacy. The number of division cycles (D1-D3) of proliferating OT-I CD8+ T cells were determined by flow cytometry
(FCM) using the FlowJo software. For each group, tissues from five mice were pooled to provide enough cells. (D) Translation of delivered Rep-NP in porcine SK-6
cells and primary dendritic cells (DCs). After incubation for 48 h at 37°C with Rep-NP complexed to PEI or packaged into VRP, the cells were washed, fixed (4%
PFA), permeabilised (saponin) and labeled with antibodies against influenza NP (green) and CSFV E2 (red); cell surfaces were stained with WGA (blue). All pictures
were generated with IMARIS 7.7 with threshold subtraction and gamma correction set as in the “RepRNA alone” control.January 2021 | Volume 11 | Article 622385
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the closer immunological relationship to humans.
Assessment of Delivery to DCs In Vitro
Before proceeding with the assessment of RepRNA delivery in
pigs, it was considered important to ascertain the efficiency with
which the polyplexes and VRPs delivered RepRNA for
translation of the inserted influenza virus genes. This was
initially determined using porcine SK-6 cells and blood DCs,
relating to our previous publications for chitosan-based, lipid-
based, and polyplex-based delivery of the RepRNA (6, 23–27).
Figure 2D shows that both the polyplexes and VRPs were able to
deliver RepRNA leading to translation of the gene encoding
influenza virus NP antigen.
VRP Immunization of Pigs Induces
Antigen-Specific Cells in Draining
Lymph Nodes
Next, we compared polyplex- and VRP-mediated delivery of
RepRNA in pigs with the immunization scheme shown in Figure
1C. Cells collected from peripheral blood and draining LNs of
immunized pigs were restimulated in vitro with CSFV E2, or
influenza virus HA/NP recombinant proteins. First, we
quantified the percentage of FSChigh cells for all unstimulated
and restimulated samples, since porcine proliferating
lymphocytes exhibit forward scatter of a higher intensity (24)
(example shown in Figures 3A, B).
Lymphocyte activity in the peripheral blood was assessed
using PBMCs derived from comparators immunized with
“RepRNA + c-di-AMP”. Polyclonal restimulation of PBMCs in
vitro employed Con A to ascertain the responsiveness of the cells.
A high and comparable percentage of FSChigh cells was observed
with cells from animals in the vaccination groups, particularly at
day 3 (Figure 3C, upper panel, Con A). This indicated that the
PBMCs retained a good and comparable intrinsic capacity for
proliferation, whether they had been exposed in vivo to
“RepRNA + c-di-AMP”, “[RepRNA/PEI] + c-di-AMP” or
“VRP”. When antigen-specific stimulation of the PBMC was
assessed with E2, HA or NP antigens, PBMCs derived from pigs
receiving “[RepRNA/PEI] + c-di-AMP” or “VRP” failed to
display a clear enriched FSChigh population in peripheral blood
on day 3 and 5 (Figure 3C, upper panel).
Lymphocytes were also derived from draining LNs. Their
responsiveness to Con A was similar to that observed in PBMCs
(Figure 3C, lower panel), implying a preserved capacity to
proliferate for all animals in the study. In contrast to PBMCs,
a more notable antigen-specific stimulation was observed,
particularly when using NP antigen. Comparators immunized
with “RepRNA + c-di-AMP” showed low evidence for specific
cell proliferation (low percentage of FSChigh cells when
resimulated in vitro with E2 and HA at day 3 and 5, whereas
an enhanced proliferation of cells was observed in two of five
pigs following NP restimulation at day 3) (Figure 3C, left lower
panel). No significant improvement was seen for the group
“[RepRNA/PEI] + c-di-AMP”. In contrast, cells derived from
draining LNs of pigs immunized with VRP gave a clear enrichedFrontiers in Immunology | www.frontiersin.org 7FSChigh population, most notable at day 5 (E2 (***), HA (**) and
NP (**)). Altogether, these results show a clear distinction
between pigs immunized with naked RepRNA or polyplexes
(weak FSChigh cell enrichment at day 3) and pigs immunized
with VRPs (specific FSChigh cell enrichment occurring in the
draining LNs at days 3-5 p.i.). This increased FSChigh cell
population strongly suggested a specific T- and B-cell response
against influenza virus antigens.
Confirmation of Antigen-Specific
Proliferation With Draining Lymph
Node Cells From Polyplex and VRP
Immunized Pigs
In order to confirm the above results, we assessed cell
proliferation by reduction in the CellTrace signal from
preloaded cells (due to cell division distributing the dye to
daughter cells). Figure 3D displays examples of the dot plots
gated on FSChigh cells from draining LNs, following NP
restimulation. Cells from comparators receiving “RepRNA + c-
di-AMP” lacked clear evidence for specific proliferation – the
percentage of CellTracelow was low, remaining stable (pig #1542)
or only slightly increased (pigs #1548 and #1552) between days 3
and 5. In contrast, cells from animals receiving “[RepRNA/PEI]
+ c-di-AMP” showed proliferation – the percentage of
CellTracelow increased between day 3 and 5. Cells from
animals immunised with VRP showed a higher proliferation –
the percentage of CellTracelow was high, with strong increases
between day 3 and 5. Altogether, these results established that
RepRNA must be correctly packaged, either in PEI-based
polyplex or in VRPs, for efficient delivery in vivo leading to
intracellular release of the RepRNA for translation of the
encoded antigens to promote specific cell proliferation in
secondary lymphoid organs. Of note, VRP were clearly more
efficient at genome delivery than the PEI-based polyplexes since
the latter required 103 times more RNA than the VRP for
comparable immune induction (see materials and methods).Polyplex and VRP Induce CD4+ T Cell
Responses Specific for Encoded Influenza
Virus Antigens
Considering the apparent advantage of VRP delivery leading to
RepRNA translation of the encoded influenza virus antigens
inducing specific immune responses, the question arose as to the
compartmentalisation of these responses. Firstly, CD4+ T cell
proliferation was measured using in vitro restimulation with E2,
HA, and NP recombinant proteins, using again the CellTrace
signal from preloaded cells as readout. By day 5, a moderate
proliferation of CD4+ T cells was observed in unstimulated wells
from certain comparators, up to seven rounds of cell division.
This background proliferation was slightly increased after in
vitro restimulation with NP. In comparison, peripheral
blood cells from pigs receiving polyplexes or VRPs also
showed a slight background proliferation of CD4+ T cells in
unstimulated wells. As with the comparators, this proliferation
increased in response to influenza virus NP, more substantiallyJanuary 2021 | Volume 11 | Article 622385




FIGURE 3 | Virus replicon particle (VRP) immunization induces specific immune cell proliferation in the draining lymph nodes. (A) The gating strategy used to
quantify B and T cell proliferation, based on the expression of CD3, CD4, CD8, CD21, IgM, and CellTrace™ markers, is shown. (B) On the left side is shown a
representative histogram, where FCSlow and FSChigh gates can be distinguished. Then, CD4+ T cells (CD3+CD21-IgM-CD4+CD8-), CD4+CD8+ T cells (CD3+CD21-
IgM-CD4+CD8+), CD8+ T cells (CD3+CD21-IgM-CD4-CD8+), and B cells (CD3-CD21+IgM+CD4-CD8-) where analyzed in parallel from those two independent FSClow
and FSChigh gates. The representative examples on the right side clearly show that proliferative cells are CellTracelow FSChigh. (C, D) At day 56 post-first
immunization, freshly isolated PBMCs and LN cells where exposed against recombinant CSFV E2 and influenza virus HA and NP, or were let unstimulated (“-”). For
all samples, Con A was used as a positive control. (C) Induction of FSChigh cell population following Ag restimulation. Cells from the individual animals are
represented by separate symbols. The percentage of FSChigh cells was determined by flow cytometry with FlowJo. (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001). (D) After 3
or 5 days of cell culture, the numbers of division cycles using CellTrace™ of proliferating cells from FSChigh subset from restimulated LN cells were determined by
flow cytometry with FlowJo. Representative animals are shown for the three animal groups “RepRNA + c-di-AMP”, “[RepRNA/PEI] + c-di-AMP” and “VRP”.Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 6223858
Démoulins et al. Pestivirus Replicon and Anti-Influenza Virus Immunityfor “[RepRNA/PEI] + c-di-AMP” group (Figure 4A ,
Peripheral blood).
The above results with LN cells from the “RepRNA + c-di-
AMP” group proved to be relatively minor compared to results
obtained with cells from pigs receiving polyplexes and VRPs.
Notably for the latter, CD4+ T cells displayed a very strong
proliferation in response to the E2, HA and NP antigens. This
was observed as a very high percentage of division peaks D5 –D7
for E2 (57.3%), HA (58.2%), and NP (56.5%), compared to
background level for the unstimulated “-” (17.9%) (Figure 4A,
Draining LNs). Dot plots for these results are shown in FigureFrontiers in Immunology | www.frontiersin.org 94B for three animals from each group. Altogether, these results
demonstrate that immunization with RepRNA packaged in PEI-
based polyplex or VRP promotes translation of encoded
antigens, likely by DCs, in pigs.
Polyplex and VRP Induce CD8+ T Cell
Responses Specific for Encoded Influenza
Virus Antigens
In addition to the above assessment of CD4+ T cell responses, the
same analysis was applied to cytotoxic CD8+ T cells. Again, PBMCs
and cells isolated from draining LNs of most pigs immunized withA B
FIGURE 4 | Virus replicon particle (VRP) and polyplex induce a strong and specific CD4+ T cell immune response against influenza antigens. Induction of CD4+ T
cell immune responses against the RepRNA encoded CSFV E2 and influenza virus HA and NP, determined by restimulation of freshly isolated PBMCs and LN cells
(day 56 post-first immunization); cells were restimulated with recombinant E2 (1 µg/ml), HA (1 µg/ml) or NP (1 µg/ml), or non-stimulated (-). (A) After 5 days of cell
culture, the numbers of division cycles (D0-D7) of proliferating CD4+ T cells in PBMC and draining LN compartments, were determined by flow cytometry using the
FlowJo software. The values represent the mean of proliferating CD4+ T cells of the five individual pigs for each group. Numbers in red represent the mean
percentage of highly proliferative cells (≥ 5 division cycles). (B) After 5 days of cell culture, representative dot plots are shown for draining LN compartments of three
immunized animals per groups for proliferating CD4+ T cells.January 2021 | Volume 11 | Article 622385
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population for accurate analysis (only one out of five pigs).
Restimulation of its CD8+ T cells with E2 and NP induced a weak
cell proliferation with peaks D5 – D7 for E2 (14.9%) and for NP
(10.8%) compared to background, unstimulated levels (“-”, 5.3%)
(Figure 5A, top panel, “Peripheral blood”). However, cells derived
from draining LNs failed to induce significant anti-E2, anti-HA or
anti-NP response, when compared to background proliferation in
unstimulatedwells (“-”.) (Figure 5A, top panel “DrainingLNs” and
Figure 5B). This supports the notion that specific proliferation in
response to the encoded influenza virus antigens was at bestFrontiers in Immunology | www.frontiersin.org 10moderate for the unique responder animal in this
vaccination group.
Like the above comparator animals, no clear anti-E2, anti-
HA, or anti-NP CD8+ T cell response responses were detectable
in peripheral blood samples of pigs immunized with “[RepRNA/
PEI] + c-di-AMP” (Figure 5A, middle panel, “Peripheral
blood”). However, cells derived from draining LNs showed
clear CD8+ immune responses against influenza antigens, and
particularly for NP (increased frequency at day 5 of peaks D5 –
D7 (Figure 5A, middle panel, “Draining LNs”). This is also
illustrated in the dot plots shown in Figure 5B. Peaks of lowA B
FIGURE 5 | Virus replicon particle (VRP) and polyplex induce a specific CD8+ T cell immune response against influenza antigens. Induction of CD8+ T cell immune
responses against the RepRNA encoded CSFV E2 and influenza virus HA and NP, determined by restimulation of freshly isolated PBMCs and cells derived from
draining LNs (day 56 post-first immunization); cells were restimulated with recombinant E2 (1 µg/ml), HA (1 µg/ml) or NP (1 µg/ml), or non-stimulated (-). (A) After 5
days of cell culture, the numbers of division cycles (D0-D7) of proliferating CD8+ T cells in PBMC and draining LN compartments, were determined by flow cytometry
using the FlowJo software. The values represent the mean of proliferating CD8+ T cells of the five individual pigs for each group. Numbers in red represent the mean
percentage of highly proliferative cells (≥ 5 division cycles). (B) After 5 days of cell culture, representative dot plots are shown for draining LN compartments of three
immunized animals per group for proliferating CD8+ T cells.January 2021 | Volume 11 | Article 622385
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percentage than those measured with CD4+ T cells.
Also for pigs immunized with “VRP”, no clear anti-E2, anti-
HA or anti-NP responses were detectable in peripheral blood
samples (Figure 5A, bottom panel, “Peripheral blood”). Again,
cells derived from draining LNs showed clear CD8+ immune
responses against influenza antigens, albeit at lower percentage
for NP than those measured in pigs immunized with polyplexes
(Figure 5A, “Draining LNs” and Figure 5B). In conclusion, the
combined observations for CD4+ and CD8+ T cells in pigs
receiving RepRNA packaged in PEI-based polyplexes or VRPs,
confirmed that the T-lymphocytes had clearly responded to
RepRNA encoded GOI (HA and NP antigens), which could
only have arisen following RepRNA translation in vivo.
VRP and Polyplex Activate CD4+CD8+ T
Cells Response Against Influenza Antigens
CD4+CD8+ double-positive (DP) lymphocytes proliferate in
response to stimulation with recall viral antigen and include
most likely memory/effector T cells [for a review see (43)]. For
PBMCs, a moderate proliferation of DP T cells was observed in
unstimulated wells from certain comparators. This background
proliferation was slightly increased after NP restimulation.
However, this clear anti-NP response was higher in pigs
receiving polyplexes (peaks D5–7 = 37.8%), whereas no clear
response were detectable in peripheral blood samples from pigs
immunized with “VRP (Figure 6A, Peripheral blood).
Once again, the above results proved to be relatively minor
compared to what observed with cells isolated from draining
LNs. DP T cells derived from pigs receiving polyplexes showed
clear DP T cell immune responses against influenza antigens
(Figure 6B). But this was moderate compared to pigs immunized
with VRPs, where DP T cells displayed a very strong
proliferation in response to E2, HA and NP (percentage of
division peaks D5 – D7: 40.0%, 44.1%, and 37.0%, respectively)
(Figure 6A, Draining LNs). This is also illustrated in the dot
plots shown in Figure 6B.
Given that DP T cells displayed strong proliferations in LN
samples following restimulation, we next wondered whether the
number of this specific subset could increase in animals receiving
either polyplexes or VRPs. Expansion could be indicative of the
induction of a memory T cell response (as shown in Figure 3A,
large differences could be seen in the frequency of this T cell
subset depending of the experimental condition). Effectively, a
significant increase in size was observed following antigen
restimulation for pigs receiving VRPs, whereas three out of five
pigs receiving polyplexes displayed a clear enrichment of DP T
cells (Figure 6C). Taken together, these results strongly suggest
that our vaccine formulations can induce an immunological T
cell memory against influenza antigens.
VRP Induce a Specific B Cell Immune
Response Against Influenza Virus Antigens
Considering the importance of the humoral response against
influenza virus, specific B cell response against the RepRNA
encoded influenza virus antigens was assessed. For PBMCsFrontiers in Immunology | www.frontiersin.org 11derived from pigs immunized with “RepRNA + c-di-AMP”
that displayed FSChigh cells, a clear anti-NP response was
observed (at day 5, peaks D5-7 = 8.2%). However, this specific
anti-NP response was higher in pigs receiving the antigens using
VRPs (peaks D5-7 = 11.7%) (Figure 7A “Peripheral blood”).
B cells derived from the LNs of comparator pigs showed no
sign of activation of E2-, NP- and HA-specific B cells,
respectively. Those readouts were also negligible in pigs
receiving polyplexes, with the slight exception of NP
restimulation. In contrast, very strong B cell proliferation was
observed in pigs receiving VRPs in response to E2, HA and
particularly NP (Figure 7A, “Draining LNs”). Figure 7B
recapitulates the percentages of CellTracelow division peaks D5
– D7 for E2 (15.7% ± 0.8), HA (17.5% ± 4.2), and NP (33.8% ±
1.5), compared to background, unstimulated levels (“-”, 7.3% ±
4.0) in pigs receiving polyplexes and VRPs.
VRP Induced Lymphocyte Responses
Translate to Antibodies Against Influenza
Virus Antigens
The above results clearly demonstrate that the VRP-delivered
RepRNA, and to a lesser extent PEI-delivered RepRNA,
translated in vivo to provide the encoded influenza virus
antigens for stimulating both T- and B-lymphocyte immune
responses. Accordingly, we considered that in vivo induction of
anti-HA and -NP specific antibodies would be possible.
However, immunization with the comparator “RepRNA + c-
di-AMP” and “[RepRNA/PEI] + c-di-AMP” were overall poor at
inducing detectable anti-HA or anti-NP antibody responses; any
detectable IgG titers were close to non-specific background levels
observed with pre-vaccination bleeds especially with the HA
antigen (Figure 7C).
Compared to the previous groups, VRP immunization
induced superior humoral responses against RepRNA-encoded
influenza virus antigens, detectable in all animals (Figure 7C:
“VRP”, anti-HA: p<0.001; anti-NP: p=0.047). Interestingly,
immunization with the HA-encoding VRP induced higher
titers than those observed following immunization with the
NP-encoding VRP. Moreover, tight grouping of the titers from
individuals was observed for anti-HA antibodies, relating also to
higher titers from all individuals (titers IgG anti-HA: 8047.9 ±
597.3; anti-NP: 1014.7 ± 957.7).
It was then considered that the anti-NP response induced by
the VRPs might be influenced by the influenza virus strain
employed for the vaccination or analyses. In order to
understand better why anti-NP IgG titers were more moderate
than the anti-HA IgG titers following VRP immunization, we
performed ELISA by coating with recombinant NP proteins
from two different influenza virus strains: A/Brisbane/10/2007
(H3N2) and A/Thailand/1(KAN-1)/2004 (H5N1). This had no
influence on the anti-NP readout compared with the anti-HA
readout (data not shown).
Taken together, these results showed that VRP immunization
induced strong anti-HA and anti-NP humoral responses.
Overall, this confirms the requirement of RepRNA to be
properly packaged for efficient translation of the GOI.January 2021 | Volume 11 | Article 622385
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FIGURE 6 | Virus replicon particle (VRP) and polyplex activate CD4+CD8+ T cells response against influenza antigens. Induction of CD4+CD8+ T cell immune
responses against the RepRNA encoded CSFV E2 and influenza virus HA and NP, determined by restimulation of freshly isolated PBMCs and cells derived from
draining LNs (day 56 post-first immunization); cells were restimulated with recombinant E2 (1 µg/ml), HA (1 µg/ml) or NP (1 µg/ml), or non-stimulated (-). (A) After 5
days of cell culture, the numbers of division cycles (D0-D7) of proliferating CD4+ T cells in PBMC and draining LN compartments, were determined by flow cytometry
using the FlowJo software. The values represent the mean of proliferating CD4+CD8+ T cells of the five individual pigs for each group. Numbers in red represent the
mean percentage of highly proliferative cells (≥ 5 division cycles). (B) After 5 days of cell culture, representative dot plots are shown for draining LN compartments of
three immunized animals per group for proliferating CD4+CD8+ T cells. (C) For the counts of CD4+CD8+ T cell subset, we calculated the percentage of total events:
ratio (number of events in the gated cell subtype: FSChighCD3+CD21-IgM-CD4+CD8+) to (number of all events). *p ≤ 0.05.Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 62238512
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FIGURE 7 | Virus replicon particle (VRP) induce a strong and specific humoral immune response against influenza antigens. Induction of B cell immune responses
against the RepRNA encoded CSFV E2 and influenza virus HA and NP, determined by restimulation of freshly isolated PBMCs and cells derived from draining LNs
(day 56 post-first immunization); cells were restimulated with recombinant E2 (1 µg/ml), HA (1 µg/ml) or NP (1 µg/ml), or non-stimulated (-). (A) After 5 days of cell
culture, the numbers of division cycles (D0-D7) of proliferating B cells in PBMC and draining LN compartments, were determined by flow cytometry using the FlowJo
software. The values represent the mean of proliferating B cells of the five individual pigs for each group. Numbers in red represent the mean percentage of highly
proliferative cells (≥ 5 division cycles). (B) After 5 days of cell culture, representative dot plots are shown for immunized animals per group for proliferating B cells.
(C) Induction of humoral immune response (IgG titer) against RepRNA encoded influenza virus HA and NP, determined by ELISA using day -5 (baseline) and day 56
(post-boost 2) sera from individual pigs. ***p < 0.001; *p < 0.05.Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 62238513
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Several mRNA-based vaccines are currently in clinical trials to
prevent COVID-19 and plan to file for emergency approval. In
comparison to mRNA, self-amplifying RepRNA require very low
dose and result in prolonged and increased transgene expression
(5). We chose CSFV RepRNA, due to its positive-strand and
non-cytopathogenic nature, thus, providing long-lasting protein
expression in the targeted cell (6, 38). This contrasts with
alphavirus and flavivirus replicons (11) derived from
cytopathogenic viruses, often resulting in high albeit short-
lived antigen expression levels; the contrast is even further
from replicons based on vesicular stomatitis virus (VSV) which
is both highly cytopathogenic and a negative strand virus
precluding application of synthetic nanoparticulate delivery.
The latter delivery has been achieved successfully using the
CSFV RepRNA (6, 23–27). This formulation protects the
highly RNase-sensitive RepRNA, and overcomes the obstacles
for naked RepRNA to survive in biological environments and
cross the cell membrane barrier to promote intracellular delivery
to DCs.
Prior to such reports on delivery of RepRNA with synthetic
nanoparticulate systems, delivery had been achieved using VRPs
(9, 13). While we have demonstrated nanoparticle delivery of
RepRNA using different formulations based on chitosan-
alginate, polyplexes including PEI-polyplexes and lipids (6, 11,
23–27, 44), there is no comparison with RepRNA packaged in
VRP (38, 39, 45). Another critical issue is that RepRNA delivery
has been assessed primarily in mice, which may not provide
accurate assessment of efficacy for humans, particularly when
targeting to DCs is sought. An alternative immunological model
closer to humans is the pig. The CSFV RepRNA has been
delivered as VRPs to pigs (38, 39, 45). Moreover, CSFV shows
at best a poor capacity to infect mice, is not applicable in humans,
but is highly infectious for pigs (46).
CSFV RepRNA delivered as VRPs have been assessed in pigs
as vaccines against CSFV (38, 39), wherein very efficient
induction of antibody responses against the main CSFV
surface glycoprotein E2, and protection against challenge virus
infection were observed (39). This work did not employ RepRNA
encoding foreign gene vaccine antigens. Moreover, information
on T-lymphocyte activity is notably sparse, and no comparison
has been made with synthetic nanoparticulate delivery,
particularly of RepRNA expressing foreign gene products such
as influenza virus antigens. Accordingly, we sought to assess
delivery of RepRNA encoding influenza virus HA and NP by
VRP in vivo, and comparing with PEI-polyplex delivery reported
as being particularly effective (24).
Pigs immunized with VRPs strongly displayed both cellular
(see Figures 4–6) and humoral responses against the RepRNA-
encoded HA and NP (see Figure 7C). The humoral response
against NP was lower than that against HA, but still notable. In
our opinion, this may reflect the observations about NP epitopes
being more important for inducing cellular immune defenses,
while HA epitopes are certainly critical for potent humoral
responses. Such readouts are considered important due to theFrontiers in Immunology | www.frontiersin.org 14requirement for activation of both cell-mediated and humoral
arms of immune defenses to confer potent immunity
against influenza.
The strong anti-HA humoral response that we observed for
the VRP group is in line with results obtained with the two forms
of vaccine currently in use: live attenuated influenza vaccines
(LAIV) and inactivated influenza vaccines (IIV). Both LAIV and
IIV induce neutralizing antibodies against the viral membrane
surface glycoproteins HA and NA [for a review, see (47)]. LAIV
is administered i.n. and contains the full complement of viral
components, whereas IIV is administered i.m. and contains
inactivated viral components, mainly purified HA antigens. In
this context, our RepRNA-based strategy – employing either
VRP or polyplex as delivery vehicles – relates to a combination of
particular elements in the LAIV (replicating vaccine providing
both HA and NP) and IIV strategies (parenteral immunization).
RepRNA coding for NP are employed for inducing the cellular
immune defenses crucial to provide cross-protective immune
responses against influenza virus [for a review, see (48)].
Cytotoxic T cell epitopes, such as those found on the NP, are
located on internal influenza virus proteins; thus it is difficult to
induce anti-NP responses, because these antigens are less
immunogenic than the surface proteins of HA and NA.
Despite several formulation strategies to induce influenza-
specific T cell responses, there is currently no T cell-based
influenza vaccine on the market (49). This makes our
RepRNA-based vaccine formulation advantageous, particularly
with VRP-delivery, since we detected strong CD4+ T cell and
significant CD8+ T cell proliferation in response to recombinant
NP (see Figures 4 and 5).
Packaging the RepRNA in a delivery vehicle ensured the
maintenance of RNA integrity in vivo, whether the packaging/
delivery employed VRPs or synthetic nanoparticles, as in our
previous reports (6, 11, 23–27, 44). Naked RepRNA is a large and
labile molecule – a single cleavage would severely impair
translation and abolish self-replication. From our studies, there
is no other option for assisting and protecting it for efficient DC
targeting. In contrast, naked RepRNA co-administered with c-di-
AMP can offer some protection to the RNA; this formulation was
only capable of translating in certain cases – detectable immune
responses against the encoded antigens were induced in one out
of five animals. This was less robust compared to the immune
responses quantified in pigs receiving packaged RepRNA – VRP
or polyplex.
In addition to the encoded vaccine antigens, the CSFV
RepRNA encodes a leader autoprotease – Npro – which
abolishes type I interferon induction (50). Therefore, to
promote DC maturation – and subsequent induction of
adaptive immune responses – an essential requirement is the
co-formulation of CSFV RepRNA with an adjuvant to activate
the pathogen–associated molecular patterns (PAMPs). Hence,
the choice of co-administrated c-di-AMP adjuvant, which
potentiates robust humoral and cellular immune responses,
including cytotoxic and multifunctional T cells – the latter
have been related to robust protective T-lymphocyte immunity
(30). In all likelihood, the chosen administration route and use ofJanuary 2021 | Volume 11 | Article 622385
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RepRNA in 20% of the animals. Indeed, c-di-AMP induces a self-
limited local activation of type I IFN and TNF by acting as
STING agonist and then targeting it to degradation (51).
Therefore, using a potent adjuvants, such as c-di-AMP, will
probably help to reduce the concentration of the RepRNA
packaged in PEIs due to the demonstrated dose sparing
capacity (29).
Previous studies on potential influenza vaccines showed that
vaccine based only on influenza virus NP proved unusable. VRP
vaccines encoding influenza virus NP alone were not efficacious
in pigs for protection against H1N1 and H1N2, leading even to
signs of enhanced inflammation in terms of increased
microscopic lung lesions, virus shedding, and increased levels
of IFN-a and IL-6 (45). Moreover, one cannot rely on evaluation
in the mouse models as guaranteeing success in other species,
including human. NP-based vaccines have been disappointing in
ferrets – considered as a good model for human influenza –
contrasting with results obtained in mice (52, 53). Although NP
represents an interesting vaccine antigen being well conserved
across subtypes, it was insufficient to confer a complete
protection to a challenge with influenza virus (54). Our
formulations have the advantage of carrying an equimolar
mixture of RepRNA encoding HA or NP influenza antigens.
This led to specific humoral and cellular responses against both
HA and NP. This is of importance, since the role of CD4+ T cell
memory in mediating a protective immunity to influenza has
gained interest the last decade [for a review, see (55)]. Moreover,
pre-existing influenza-specific CD4+ T cells, but not CD8+ T
cells, correlate with disease protection against pandemic H1N1
(A/CA/07/2009) in humans (56). Altogether, these findings
highlight the importance to target several antigens to induce a
broader immune response against influenza virus.
Our goal has been to generate RepRNA constructs as the
specific active ingredient of influenza vaccines, with the potential
for inducing broader and more robust immunity than the
current seasonal, inactivated vaccines. Due to frequent
antigenic changes of influenza viruses in the human
population, current seasonal influenza vaccines must be
updated annually to include the latest predicted strains. The
design of a new CSFV RepRNA constructs encoding influenza
virus antigen from any new isolate is a rapid and cost-effective
strategy: our current RepRNA carries insertion sites that
efficiently facilitate the accommodation of influenza virus genes
of interest for broad protection against the virus. Technically,
update of a CSFV RepRNA construct employs standard
molecular biology methods to replace the GOI by an influenza
virus gene (NP, HA but also neuraminidase (NA), M1 or M2)
encoding antigen of the new reported isolates (57). Protection
against a wide range of strains/subtypes would require a vaccine
formulation mixing several RepRNA constructs carrying
influenza virus genes from different strains. For the pigs
employed in this study, the vaccine contained RepRNA
encoding as GOI either the HA or NP from Influenza A/
chicken/Yamaguchi/7/2004 (H5N1), a highly pathogenic avian
influenza virus that remains a public health threat (37). ThisFrontiers in Immunology | www.frontiersin.org 15experimental approach proved to be efficient, since significant B
cells, CD4+ and CD8+ T cell responses were readily detected
against the RepRNA-encoded influenza virus HA and NP;
moreover the increased cell number and proliferation level of
the CD4+CD8+ T cell suggested the induction of a memory
response (58, 59). In order to consolidate these results, the next
step will be a broader formulation comprising Rep-NP and a
panel of Rep-HA encoding for seasonal and pandemic influenza
virus antigens (H1N1, H5N1, H7N1). The aim is to determine
the level of heterosubtypic protection.
In conclusion, the present study demonstrates that
immunization of large mammals with a combination of
RepRNA encoding the H5N1 NP or H5N1 HA induces strong
T- and B cell responses against both influenza antigens, relating
to the capacity of VRPs – and to a lesser extent poyplexes – for
targeting DCs for translation of the delivered RepRNA. This
knowledge is being applied to facilitate exploitation of the full
potential of RepRNA delivery platforms in the context of
universal influenza vaccine design. The rapidity by which Rep-
HA can be updated could circumvent the limitation of current
vaccines that are strain-specific due to their focus on the
immunodominant globular head domain of the HA (60). In
our case, the encoding of complete HA protein most probably
promotes the induction of antibodies reactive against both
divergent head domains and conserved stalk. A sequential
exposure to Rep-HA from different strains – or alternatively a
vaccine formulation mixing Rep-HA harboring sequences of
various strains – will increase the chance that immune
responses broadly neutralize epitopes in the stalk. The use of
recombinant NA as a vaccine antigen proved to have
homologous and heterologous protective capacity (61).
Altogether, this suggests that a RepRNA-based vaccine
formulation comprising conserved Rep-NP, several Rep-HA
encoding several influenza strains (seasonal plus pandemic
H1N1, H5N1, H7N1), as well as the NA subunit, in
combination with a potent adjuvant would facilitate the design
of a universal influenza vaccine. Finally, the rapidity with which
RepRNA can be modified and formulated with the delivery
vehicle will be of great help to tackle emergencies, such as the
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